Revance’s Botox rival gets FDA approval for painful neck muscle conditionTherapeuticsThe approval by the Food and Drug Administration helps Revance enter the $2.5 billion U.S. market for therapeutic neuromodulator, a method that directly acts on nerves, the company said on Monday. Read more August 14, 2023/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2022/05/FDA-declines-to-authorize-common-antidepressant-as-COVID-treatment-Reuters-5-16-22.jpg 628 1200 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2023-08-14 08:05:522023-08-14 09:33:45Revance’s Botox rival gets FDA approval for painful neck muscle condition
